2002
DOI: 10.1086/339187
|View full text |Cite
|
Sign up to set email alerts
|

Merozoite Surface Protein 3 and Protection against Malaria inAotus nancymaiMonkeys

Abstract: A blood-stage vaccine based on Plasmodium falciparum merozoite surface protein 3 (MSP3) was tested for efficacy in a primate model. Aotus nancymai monkeys were vaccinated with yeast-expressed MSP3 before a lethal challenge with Plasmodium falciparum parasites. Five of 7 control monkeys had acute infections and required treatment to control parasitemia. Only 1 of 7 monkeys vaccinated with MSP3 required this treatment. The efficacy of the MSP3 vaccination appeared to be comparable to that of MSP1(42), a leading … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

8
66
0
3

Year Published

2002
2002
2018
2018

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 74 publications
(77 citation statements)
references
References 35 publications
8
66
0
3
Order By: Relevance
“…[36][37][38] Several other molecules are being channelled into human trials on the basis of results considered promising and obtained in one of the primate, mouse, or in-vitro models (figure 1). [39][40][41][42][43] Clinical trials will be essential to show whether these results can be extended to human beings.…”
Section: Personal Viewmentioning
confidence: 99%
“…[36][37][38] Several other molecules are being channelled into human trials on the basis of results considered promising and obtained in one of the primate, mouse, or in-vitro models (figure 1). [39][40][41][42][43] Clinical trials will be essential to show whether these results can be extended to human beings.…”
Section: Personal Viewmentioning
confidence: 99%
“…Immunization with recombinant forms of MSP3 protected monkeys against malaria infection (8). A vaccine based on MSP3 N-terminal fragment is already in human trials (9,10).…”
mentioning
confidence: 99%
“…Immunizations with several forms of recombinant MSP3 were each shown to protect monkeys against parasite challenge (4,5). MSP3-specific antibodies in the presence of monocytes mediated killing of parasites in an antibody-dependent cellular inhibition assay (6).…”
mentioning
confidence: 99%